Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) released its earnings results on Friday. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.14), Zacks reports. The firm had revenue of $10.09 million during the quarter, compared to analysts' expectations of $50.00 million. During the same quarter last year, the company posted ($0.23) earnings per share.
Autolus Therapeutics Trading Down 8.4 %
Shares of AUTL traded down $0.37 during midday trading on Monday, hitting $4.02. 1,447,622 shares of the company's stock traded hands, compared to its average volume of 1,688,358. Autolus Therapeutics has a 1 year low of $2.01 and a 1 year high of $7.45. The firm's fifty day moving average is $4.99 and its 200-day moving average is $5.36. The stock has a market capitalization of $1.07 billion, a price-to-earnings ratio of -3.35 and a beta of 2.03.
Analysts Set New Price Targets
A number of research firms have recently commented on AUTL. Needham & Company LLC reaffirmed a "buy" rating and set a $9.00 target price on shares of Autolus Therapeutics in a research note on Friday. Truist Financial increased their price objective on Autolus Therapeutics from $10.00 to $11.00 and gave the stock a "buy" rating in a research note on Tuesday, April 9th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $8.70.
Read Our Latest Research Report on AUTL
Autolus Therapeutics Company Profile
(
Get Free Report)
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.
Featured Articles
Before you consider Autolus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Autolus Therapeutics wasn't on the list.
While Autolus Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
